EP0682027B1
(fr)
*
|
1994-05-03 |
1997-10-15 |
Novartis AG |
Dérivés de la pyrrolopyrimidine avec une activité anti-proliférative
|
TW321649B
(fr)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
WO1996031510A1
(fr)
*
|
1995-04-03 |
1996-10-10 |
Novartis Ag |
Derives de pyrazole et leurs procedes de preparation
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
DE69613367T2
(de)
*
|
1995-04-27 |
2002-04-18 |
Astrazeneca Ab, Soedertaelje |
Chinazolin derivate
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US6140332A
(en)
*
|
1995-07-06 |
2000-10-31 |
Novartis Ag |
Pyrrolopyrimidines and processes for the preparation thereof
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
EP0888349B1
(fr)
*
|
1996-01-23 |
2002-05-22 |
Novartis AG |
Pyrrolopyrimidines et leurs procedes de preparation
|
WO1997030035A1
(fr)
|
1996-02-13 |
1997-08-21 |
Zeneca Limited |
Derives de la quinazoline utilises comme inhibiteurs du vegf
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
WO1997032856A1
(fr)
|
1996-03-05 |
1997-09-12 |
Zeneca Limited |
Derives de 4-anilinoquinazoline
|
ATE213730T1
(de)
|
1996-04-12 |
2002-03-15 |
Warner Lambert Co |
Umkehrbare inhibitoren von tyrosin kinasen
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
AU3176297A
(en)
*
|
1996-06-25 |
1998-01-14 |
Novartis Ag |
Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
|
DE69738468T2
(de)
|
1996-08-23 |
2009-01-08 |
Novartis Ag |
Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung
|
EP0929553B1
(fr)
|
1996-10-02 |
2005-03-16 |
Novartis AG |
Derives de pyrimidine et procedes de preparation de ces derniers
|
US6225318B1
(en)
|
1996-10-17 |
2001-05-01 |
Pfizer Inc |
4-aminoquinazolone derivatives
|
CA2272705C
(fr)
|
1996-11-27 |
2003-03-18 |
Pfizer Inc. |
Derives de pyrimidines bicycliques fusionnes
|
BR9814458A
(pt)
|
1997-09-02 |
2001-10-23 |
Du Pont Pharm Co |
Composto, composição farmacêutica e método de tratamento de disfunções afetivas
|
EP1028964A1
(fr)
*
|
1997-11-11 |
2000-08-23 |
Pfizer Products Inc. |
Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
|
JPH11236333A
(ja)
*
|
1997-12-30 |
1999-08-31 |
Pfizer Prod Inc |
抗ガン剤として有用なイミダゾリン−4−オン誘導体
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
US6187777B1
(en)
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
ES2356886T3
(es)
|
1998-03-31 |
2011-04-14 |
Kyowa Hakko Kirin Co., Ltd. |
Compuestos heterocíclicos nitrogenados.
|
TW505646B
(en)
*
|
1998-06-19 |
2002-10-11 |
Pfizer Prod Inc |
Pyrrolo [2,3-d] pyrimidine compounds
|
PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
WO2000023444A1
(fr)
*
|
1998-10-21 |
2000-04-27 |
Abbott Laboratories |
Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
|
US6174903B1
(en)
|
1998-12-28 |
2001-01-16 |
Pfizer Inc. |
Imidazolidin-4-one derivatives useful as anticancer agents
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
*
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
WO2001004111A1
(fr)
|
1999-07-09 |
2001-01-18 |
Glaxo Group Limited |
Anilino-quinazolines comme inhibiteurs de la proteine tyrosine kinase
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
HUP0202713A3
(en)
|
1999-09-15 |
2005-02-28 |
Warner Lambert Co |
Pteridinones as kinase inhibitors
|
GB9925958D0
(en)
*
|
1999-11-02 |
1999-12-29 |
Bundred Nigel J |
Therapeutic use
|
UA72946C2
(uk)
|
1999-11-05 |
2005-05-16 |
Астразенека Аб |
Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
|
JP2001142235A
(ja)
|
1999-11-17 |
2001-05-25 |
Fuji Denki Gazo Device Kk |
電子写真用感光体
|
PL218519B1
(pl)
|
1999-12-10 |
2014-12-31 |
Pfizer Prod Inc |
Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie
|
AU2001252463A1
(en)
|
2000-06-06 |
2001-12-17 |
Pfizer Products Inc. |
Thiophene derivatives useful as anticancer agents
|
SK17342002A3
(sk)
|
2000-06-26 |
2004-06-08 |
Pfizer Products Inc. |
Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu
|
WO2002024667A1
(fr)
|
2000-09-20 |
2002-03-28 |
Merck Patent Gmbh |
4-amino-quinazolines
|
RU2264389C3
(ru)
|
2000-10-20 |
2018-06-01 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
|
DE60212487T2
(de)
|
2001-04-13 |
2006-12-21 |
Pfizer Products Inc., Groton |
Bizyklisch substituierte 4-Aminopyridopyrimidinderivate
|
US7301023B2
(en)
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
CZ294535B6
(cs)
*
|
2001-08-02 |
2005-01-12 |
Ústav Experimentální Botaniky Avčr |
Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
CA2472619A1
(fr)
|
2002-01-10 |
2003-07-24 |
Bayer Corporation |
Derives de pyrimidine fusionnes en tant qu'inhibiteurs de la rho-kinase
|
CN1627944A
(zh)
|
2002-01-17 |
2005-06-15 |
神经能质公司 |
取代的喹唑啉-4-基胺类似物作为辣椒辣素调节剂
|
CA2473910C
(fr)
|
2002-01-23 |
2011-03-15 |
Bayer Pharmaceuticals Corporation |
Derives de pyrimidine en tant qu'inhibiteurs de la rho-kinase
|
JP4469179B2
(ja)
|
2002-01-23 |
2010-05-26 |
バイエル ファーマセチカル コーポレーション |
Rhoキナーゼ阻害剤としてのピリミジン誘導体
|
JP2003238561A
(ja)
|
2002-02-13 |
2003-08-27 |
Fuji Denki Gazo Device Kk |
キノメタン化合物
|
MXPA04008403A
(es)
|
2002-03-01 |
2004-11-26 |
Pfizer |
Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso.
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
EP1572213A1
(fr)
|
2002-11-26 |
2005-09-14 |
Pfizer Products Inc. |
Methode de traitement d'un rejet de greffe
|
AU2004206870A1
(en)
|
2003-01-17 |
2004-08-05 |
Threshold Pharmaceuticals, Inc. |
Treatment of benign prostatic hyperplasia using energolytic agents
|
FR2851248B1
(fr)
*
|
2003-02-18 |
2005-04-08 |
Aventis Pharma Sa |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
|
AP2064A
(en)
|
2003-05-22 |
2009-10-30 |
Nerviano Medical Sciences Srl |
Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
|
MXPA06001758A
(es)
*
|
2003-08-15 |
2006-08-11 |
Irm Llc |
Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
|
US7338957B2
(en)
*
|
2003-08-28 |
2008-03-04 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
BRPI0413876A
(pt)
|
2003-08-29 |
2006-10-24 |
Pfizer |
tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
CN100450998C
(zh)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
脲衍生物的制备方法
|
BRPI0418102A
(pt)
|
2003-12-23 |
2007-04-27 |
Pfizer |
derivados de quinolina
|
WO2005095419A1
(fr)
*
|
2004-04-01 |
2005-10-13 |
Takeda Pharmaceutial Company Limited |
Dérivé de thiazolopyrimidine
|
JP4842929B2
(ja)
|
2004-05-27 |
2011-12-21 |
ファイザー・プロダクツ・インク |
癌治療に有用なピロロピリミジン誘導体
|
CA2569016C
(fr)
*
|
2004-06-02 |
2012-11-27 |
Takeda Pharmaceutical Company Limited |
Compose heterocyclique fusionne
|
CN1993362B
(zh)
*
|
2004-06-02 |
2010-12-15 |
武田药品工业株式会社 |
稠合的杂环化合物
|
EP1797881B1
(fr)
|
2004-09-17 |
2009-04-15 |
Eisai R&D Management Co., Ltd. |
Composition medicamenteuse avec une stabilite amelioree et une tendence de gelification reduite
|
EP1838712B8
(fr)
*
|
2004-12-14 |
2011-10-12 |
AstraZeneca AB |
Composes de pyrazolopyrimidine en tant qu`agents antitumoraux
|
US7423043B2
(en)
|
2005-02-18 |
2008-09-09 |
Lexicon Pharmaceuticals, Inc. |
4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
|
JP2008531542A
(ja)
*
|
2005-02-24 |
2008-08-14 |
ファイザー・プロダクツ・インク |
抗癌剤として有用な二環式複素芳香族誘導体
|
PL1899334T3
(pl)
*
|
2005-06-17 |
2009-04-30 |
Janssen Pharmaceutica Nv |
Związki naftyrydynowe
|
EP2281901B1
(fr)
|
2005-08-02 |
2013-11-27 |
Eisai R&D Management Co., Ltd. |
Composition pharmaceutique anti-tumeur avec des inhibiteurs d'angiogénèse
|
CN102702194A
(zh)
|
2005-12-21 |
2012-10-03 |
雅培制药有限公司 |
抗病毒化合物
|
JP2009521479A
(ja)
|
2005-12-21 |
2009-06-04 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
WO2007081517A2
(fr)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Composes anti-viraux
|
WO2007117465A2
(fr)
*
|
2006-03-31 |
2007-10-18 |
Abbott Laboratories |
Composés d'indazole
|
KR20120051760A
(ko)
*
|
2006-04-04 |
2012-05-22 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
키나제 길항물질
|
JP5190361B2
(ja)
|
2006-05-18 |
2013-04-24 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
甲状腺癌に対する抗腫瘍剤
|
EP1889847A1
(fr)
*
|
2006-07-10 |
2008-02-20 |
DeveloGen Aktiengesellschaft |
Dérivés de pyrrolopyrimidine pour applications pharmaceutiques
|
EP2065372B1
(fr)
|
2006-08-28 |
2012-11-28 |
Eisai R&D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
BRPI0720169A2
(pt)
*
|
2006-12-12 |
2013-12-24 |
Takeda Pharmaceutical |
Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
|
TWI399380B
(zh)
|
2006-12-20 |
2013-06-21 |
Abbott Lab |
抗病毒化合物
|
WO2008093855A1
(fr)
|
2007-01-29 |
2008-08-07 |
Eisai R & D Management Co., Ltd. |
Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
|
CN101848895B
(zh)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
血管新生抑制物质和抗肿瘤性铂络合物的组合使用
|
PE20091580A1
(es)
|
2008-03-12 |
2009-11-05 |
Takeda Pharmaceutical |
Compuesto heterociclico fusionado
|
WO2010014939A1
(fr)
*
|
2008-07-31 |
2010-02-04 |
Genentech, Inc. |
Composés de pyrimidine, compositions et procédés d'utilisation
|
WO2010020905A1
(fr)
|
2008-08-20 |
2010-02-25 |
Pfizer Inc. |
Composés pyrrolo[2,3-d]pyrimidines
|
TW201014860A
(en)
|
2008-09-08 |
2010-04-16 |
Boehringer Ingelheim Int |
New chemical compounds
|
KR101126736B1
(ko)
*
|
2008-11-27 |
2012-04-12 |
주식회사 레고켐 바이오사이언스 |
티로신 키나아제 저해 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 약학적 조성물
|
EP2387563B2
(fr)
|
2009-01-16 |
2022-04-27 |
Exelixis, Inc. |
Sel de malate de n-(4-{[6,7-bis(méthyloxy)quinolin-4-yl]oxy}phényl)-n'-(4-fluorophényl)cyclopropane-1,1-dicarboxamide et formes cristallines de celui-ci pour le traitement du cancer
|
DE102009005193A1
(de)
*
|
2009-01-20 |
2010-07-22 |
Merck Patent Gmbh |
Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
|
CA2752265A1
(fr)
|
2009-02-17 |
2010-08-26 |
Boehringer Ingelheim International Gmbh |
Derives pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
CA2780018C
(fr)
|
2009-11-12 |
2015-10-20 |
F. Hoffmann-La Roche Ag |
Composes de pyrazolopyrimidine et de purine n-7-substitues, compositions et procedes d'utilisation correspondants
|
KR101469334B1
(ko)
|
2009-11-12 |
2014-12-04 |
에프. 호프만-라 로슈 아게 |
N-9-치환된 퓨린 화합물, 조성물 및 사용 방법
|
WO2011097087A1
(fr)
*
|
2010-02-05 |
2011-08-11 |
Pfizer Inc. |
Composés d'urée à base de pyrrolo[2,3-d]pyrimidine à titre d'inhibiteurs de jak
|
AU2011270165B2
(en)
|
2010-06-25 |
2015-12-24 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
ES2545352T3
(es)
*
|
2010-08-27 |
2015-09-10 |
Merck Patent Gmbh |
Derivados de la furopiridina
|
EP2614065B1
(fr)
|
2010-12-17 |
2017-04-19 |
Nerviano Medical Sciences S.r.l. |
Dérivés de pyrazolo-quinazoline substitués à titre d'inhibiteurs de kinases
|
AU2012225693A1
(en)
|
2011-03-04 |
2013-09-19 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
WO2012144463A1
(fr)
|
2011-04-18 |
2012-10-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Agent thérapeutique pour les tumeurs
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
JP6097770B2
(ja)
*
|
2012-02-21 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
フロピリジン誘導体
|
CA2885787A1
(fr)
|
2012-09-26 |
2014-04-03 |
Lars Wortmann |
Indazol-pyrrolopyrimidines substituees utiles dans le traitement de troubles hyperproliferatifs
|
JP2015535833A
(ja)
|
2012-09-26 |
2015-12-17 |
バイエル・ファルマ・アクティエンゲゼルシャフト |
過剰増殖疾患の治療において有用な置換インダゾール−ピロロピリミジン
|
CN104755463A
(zh)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
非晶态形式的喹啉衍生物及其生产方法
|
CN105377845B
(zh)
*
|
2013-02-01 |
2017-11-24 |
拜耳制药股份公司 |
取代的吡唑并嘧啶基氨基‑吲唑类
|
WO2014145576A2
(fr)
*
|
2013-03-15 |
2014-09-18 |
Northwestern University |
Pyrrolo(2,3-d)pyrimidines substituées pour le traitement du cancer
|
US10517861B2
(en)
|
2013-05-14 |
2019-12-31 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
KR102538658B1
(ko)
|
2014-08-04 |
2023-05-31 |
누에볼루션 에이/에스 |
염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체
|
ES2926687T3
(es)
|
2014-08-28 |
2022-10-27 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y método para su producción
|
PL3263106T3
(pl)
|
2015-02-25 |
2024-04-02 |
Eisai R&D Management Co., Ltd. |
Sposób tłumienia goryczy pochodnej chinoliny
|
WO2016140717A1
(fr)
|
2015-03-04 |
2016-09-09 |
Merck Sharp & Dohme Corp. |
Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
|
ES2886107T3
(es)
|
2015-06-16 |
2021-12-16 |
Prism Biolab Co Ltd |
Antineoplásico
|
GB201520499D0
(en)
*
|
2015-11-20 |
2016-01-06 |
Medical Res Council Technology |
Compounds
|
CN106831779B
(zh)
*
|
2015-11-28 |
2019-07-19 |
南昌弘益药业有限公司 |
一类jak激酶抑制剂的新化合物
|
CA3160522A1
(fr)
|
2019-12-20 |
2021-06-24 |
Sanne Schroder Glad |
Composes actifs vis-a-vis des recepteurs nucleaires
|
WO2021198956A1
(fr)
|
2020-03-31 |
2021-10-07 |
Nuevolution A/S |
Composés actifs vis-à-vis des récepteurs nucléaires
|
WO2021198955A1
(fr)
|
2020-03-31 |
2021-10-07 |
Nuevolution A/S |
Composés actifs vis-à-vis des récepteurs nucléaires
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|